Sinomab Bioscience Limited is a Hong Kong-based biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of therapeutics for immunological diseases. Established in 2001 by antibody and biotechnology experts, it focuses on monoclonal antibody-based biologics and new chemical entities targeting conditions like rheumatoid arthritis, systemic lupus erythematosus, asthma, pemphigus, Sjogren’s syndrome, and non-Hodgkin’s lymphoma. Its flagship product, SM03 (Suciraslimab), represents a global first-in-class anti-CD22 monoclonal antibody that has completed Phase III clinical trials for rheumatoid arthritis in China, with a biologics license application accepted by Chinese regulators in 2023. The company maintains its headquarters and R&D base in Hong Kong Science Park, alongside a production facility in mainland China. With approximately 95 employees, Sinomab Bioscience Limited advances innovative treatments addressing significant unmet needs in autoimmune and inflammatory disorders, contributing to the biopharmaceutical sector's growth in Asia.